Monkeypox vaccine – Current status

From a long time ago, there have been intermittent outbreaks of the zoonotic disease monkeypox (mpox) throughout Africa. The first case of human mpox was documented in 1970 in rural Congo. Mpox was classified as a Public Health Emergency of International Concern by the WHO on July 23, 2022. India began to record its first occurrences on August 21, 2022. Smallpox and immunization history are intertwined. Although there is a lack of clinical evidence, smallpox immunizations are anticipated to offer some protection against mpox. The first-generation smallpox vaccine was a VACV preparation produced by propagating the virus on calf (or other animals) skin. Today, VARV vaccine strains are produced in mammalian cell cultures and are referred to as second-generation smallpox vaccines ACAM2000, and a “second generation” smallpox vaccine is derived from a clone of Dryvax, purified and produced using modern cell culture. Some of the more recent and secure second- and third-generation smallpox vaccines may be helpful. After smallpox was eliminated from the world, routine vaccination against smallpox among the general public was stopped because it was no longer needed. New version of smallpox/monkeypox vaccine (JYNNEOS™) is made using weakened live vaccinia virus and cannot cause smallpox, mpox, or any other infectious disease. Hence, it has been approved against mpox. Currently, postexposure prophylaxis is advised within 4 days of exposure, and preexposure prophylaxis is only advised for medical personnel at high risk of exposure. At this time, mass immunization is not advised.